Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
BioXcel Therapeutics to cut workforce 58%, stock falls 27%
08:10am, Monday, 14'th Aug 2023
Shares of BioXcel Therapeutics BTAI, +0.14% tumbled 27% premarket on Monday as the biopharma company said it would cut its workforce by about 58%. BioXcel, which uses artificial intelligence to develo
BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023
07:00am, Monday, 31'st Jul 2023
NEW HAVEN, Conn., July 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici
3 Biotech Stocks to Sell Before They Damage Your Portfolio
05:33pm, Wednesday, 12'th Jul 2023
There are several reasons that investors should be cautious about buying or holding biotech stocks at this point. First, the Street is generally bearish on the sector lately.
Why BioXcel Therapeutics Stock Was Bouncing Back This Week
08:16am, Friday, 07'th Jul 2023
The biotech was in the running for Comeback Stock of the Week. It had tanked significantly after publishing the results of a clinical trial.
BioXcel: Data Integrity Concerns Muddy Regulatory Outlook (Rating Downgrade)
06:27pm, Friday, 30'th Jun 2023
BioXcel Therapeutics faces regulatory challenges after the FDA found inconsistencies in one of its clinical trial sites, jeopardizing the supplementary approval of its drug, IGALMI. BioXcel's initiate
Why Shares of BioXcel Therapeutics Are Plunging Thursday
11:33am, Thursday, 29'th Jun 2023
The company said phase 3 trial results for BXCL501 were generally positive. BioXcel said there was a question regarding one of the trial site's investigators.
Why Is BioXcel Therapeutics (BTAI) Stock Down 57% Today?
08:57am, Thursday, 29'th Jun 2023
BioXcel Therapeutics (NASDAQ: BTAI ) stock is taking a beating on Thursday after the company released its latest clinical trial data. BioXcel Therapeutics notes that its Phase 3 clinical trial of BXC
BioXcel Therapeutics's drug meets key trial goal to treat Alzheimer's patients
06:20am, Thursday, 29'th Jun 2023
BioXcel Therapeutics said on Thursday its experimental drug to treat agitation related to Alzheimer's disease met the main goal in a late-stage study, but the results were marred by concerns over data
3 Short-Squeeze Stocks Set for a Spectacular Gamma Squeeze Rally
09:46pm, Thursday, 15'th Jun 2023
At the heart of every idea for short-squeeze stocks to buy is the ability to make a massive amount of money in a short time period. For a quick recap, those attempting to spark a gamma squeeze essenti
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
07:00am, Thursday, 01'st Jun 2023
NEW HAVEN, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici
BioXcel Therapeutics: Serenity III Part 1 Didn't Meet Primary Endpoints, Part 2 Will
09:07pm, Sunday, 28'th May 2023
BioXcel has just published the results of the first part of the Serenity III trial in which, although clinically good results, it has not been able to achieve statistically significant. This first par
Why Shares of BioXcel Therapeutics Are Dropping Thursday
12:40pm, Thursday, 25'th May 2023
BioXcel Therapeutics got approval last year for Igalmi to treat acute agitation in adults with schizophrenia or bipolar disorder. The drug is in a trial to treat patients in an at-home setting.
BioXcel Stock Crashes 22% As Bid To Double Its Market Appears Less Certain
12:04pm, Thursday, 25'th May 2023
Shares of BTAI stock plummeted after BioXcel's Igalmi missed the mark in patients with agitation due to schizophrenia or bipolar disorders. The post BioXcel Stock Crashes 22% As Bid To Double Its Mark
Why These 3 Nasdaq Stocks Were Glowing Green This Week
03:13pm, Thursday, 11'th May 2023
A fair number of Nasdaq-listed growth stocks moved higher this week. CRISPR Therapeutics, BioXcel Therapeutics, and Verve Therapeutics were among the biggest winners this week.
Why BioXcel Therapeutics Stock Marched Higher Today
04:54pm, Monday, 08'th May 2023
BioXcel Therapeutics announced 2023 first-quarter earnings today. While revenue for the three-month period wasn't a needle-mover, investors appear to be intrigued by a series of upcoming trial readout
